Elevation Oncology Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 38

Employees

  • Latest Deal Type
  • M&A

  • Investors
  • 1

Elevation Oncology General Information

Description

Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.

Contact Information

Formerly Known As
14ner Oncology
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 101 Federal Street
  • Suite 1900
  • Boston, MA 02110
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 101 Federal Street
  • Suite 1900
  • Boston, MA 02110
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Elevation Oncology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 23-Jul-2025 Completed Clinical Trials - Phase 2
4. 2PO 09-Jun-2023 Completed Generating Revenue
3. IPO 25-Jun-2021 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series B) 12-Nov-2020 $65M $95M Completed Startup
1. Early Stage VC (Series A) 16-Jan-2020 $30M $30M Completed Startup
To view Elevation Oncology’s complete valuation and funding history, request access »

Elevation Oncology Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
To view Elevation Oncology’s complete cap table history, request access »

Elevation Oncology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients
Drug Discovery
Boston, MA
38 As of 2025

Dallas, TX
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Elevation Oncology Competitors (84)

One of Elevation Oncology’s 84 competitors is Instil Bio, a Formerly VC-backed company based in Dallas, TX.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Instil Bio Formerly VC-backed Dallas, TX
Poseida Therapeutics Formerly VC-backed San Diego, CA
Kite Pharma Formerly VC-backed Santa Monica, CA
Obsidian Therapeutics Formerly VC-backed Cambridge, MA
Allogene Therapeutics Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 84 competitors. Get the full list »

Elevation Oncology Patents

Elevation Oncology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026226759-A1 Anti-her3 antibody-drug conjugates and uses thereof Pending 24-Apr-2025
EP-4304636-A1 Dosage and administration of anti-erbb3 (her3) monoclonal antibodies to treat tumors associated with neuregulin 1 (nrg1) gene fusions Inactive 11-Mar-2021
US-20220288204-A1 Dosage and administration of anti-erbb3 (her3) monoclonal antibodies to treat tumors associated with neuregulin 1 (nrg1) gene fusions Inactive 11-Mar-2021
WO-2022192534-A1 Dosage and administration of anti-erbb3 (her3) monoclonal antibodies to treat tumors associated with neuregulin 1 (nrg1) gene fusions Inactive 11-Mar-2021
US-20140079703-A1 Combination therapies comprising anti-erbb3 agents Active 30-Aug-2012 C07K16/32
To view Elevation Oncology’s complete patent history, request access »

Elevation Oncology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Elevation Oncology Former Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Aisling Capital Venture Capital Minority
BVF Partners Hedge Fund Minority
Boxer Capital Corporate Venture Capital Minority
Driehaus Capital Management Corporation Minority
Janus Henderson Investors Asset Manager Minority
You’re viewing 5 of 13 investors. Get the full list »

Elevation Oncology Investments (1)

Elevation Oncology’s most recent deal was a Corporate Asset Purchase with Merrimack Pharmaceuticals (anti-HER3 programs). The deal was made on 01-Jul-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Merrimack Pharmaceuticals (anti-HER3 programs) 01-Jul-2019 Corporate Asset Purchase Buildings and Property
To view Elevation Oncology’s complete investments history, request access »

Elevation Oncology ESG

Risk Overview

Risk Rating

Updated August, 31, 2025

38.28 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,271

Rank

Percentile

Pharmaceuticals

Industry

of 908

Rank

Percentile

Biotechnology

Subindustry

of 434

Rank

Percentile

To view Elevation Oncology’s complete esg history, request access »

Elevation Oncology FAQs

  • When was Elevation Oncology founded?

    Elevation Oncology was founded in 2019.

  • Where is Elevation Oncology headquartered?

    Elevation Oncology is headquartered in Boston, MA.

  • What is the size of Elevation Oncology?

    Elevation Oncology has 38 total employees.

  • What industry is Elevation Oncology in?

    Elevation Oncology’s primary industry is Drug Discovery.

  • Is Elevation Oncology a private or public company?

    Elevation Oncology is a Private company.

  • What is Elevation Oncology’s current revenue?

    The current revenue for Elevation Oncology is .

  • How much funding has Elevation Oncology raised over time?

    Elevation Oncology has raised $235M.

  • Who are Elevation Oncology’s investors?

    Aisling Capital, BVF Partners, Boxer Capital, Driehaus Capital Management, and Janus Henderson Investors are 5 of 13 investors who have invested in Elevation Oncology.

  • Who are Elevation Oncology’s competitors?

    Instil Bio, Poseida Therapeutics, Kite Pharma, Obsidian Therapeutics, and Allogene Therapeutics are some of the 84 competitors of Elevation Oncology.

  • When was Elevation Oncology acquired?

    Elevation Oncology was acquired on 23-Jul-2025.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process